Wisp Surpasses One Million Patients Served and Rolls Out Ambitious Growth Plan

The Telehealth Company Has Solidified Itself as a Leader and Advocate Across Women’s Healthcare for Every Stage of Women’s Lives

• Wisp surpasses one million patients, solidifying its status as the largest and fastest-growing sexual and reproductive telehealth platform in the United States.
• Wisp has achieved a 4 year CAGR¹ of 69%, with less than $2 million in primary capital, highlighting its efficient and scalable growth model.
• July 2024 annualized revenue run rate is now nearly $80 million for the first time.
• Wisp continues to innovate with the launch of over ten new products, including expanded offerings in fertility, menopause, and at-home testing.

NEW YORK--(BUSINESS WIRE)--Wisp, the fastest growing sexual and reproductive telehealth provider in the U.S, has officially surpassed one million patients served nationwide. This milestone firmly establishes Wisp as the largest telehealth platform for women, offering innovative and first-to-market products throughout every stage of a women’s health journey.

“Reaching well over one million patients and continuing our revenue run rate to nearly $80 million with profitability is a profound testament to Wisp’s mission to redefine women’s health with a focus on sexual and reproductive healthcare,” said Monica Cepak, CEO of Wisp. “With 10% of our patient base residing in areas of the US where there are significant impediments to access care, we are dedicated to expanding access to essential healthcare services. As we look ahead, we are eager to not only enhance our offerings in diagnostics, fertility, and menopause care, but we are also gearing up for some of our most ambitious product launches to date, expected later this year.”

Wisp has achieved a 4-year CAGR¹ of 69%, with less than $2 million in primary capital, highlighting its scalable and capital-light growth model. This remarkable growth, driven by strong demand for Wisp’s innovative healthcare solutions, has allowed the company to generate positive EBITDA since 2021.

In 2024, Wisp introduced over ten new products, including a fertility vertical and the Wisp+ Membership Program, designed to meet the growing needs of patients seeking treatments for conditions such as yeast infections, bacterial vaginosis (BV), herpes, and urinary tract infections (UTIs). Looking ahead, Wisp plans to further expand its offerings in menopause care, UTI treatment, and at-home testing options in addition to areas of healthcare important to women. The company’s commitment to innovation is highlighted by its pioneering first-to-market launch of DoxyPEP, a breakthrough ‘morning after pill’ for STIs and STDs, underscoring Wisp’s dedication to advancing women’s healthcare.

Wisp’s patient-centric approach allows individuals to access the treatments they need with ease, discretion, and without the need for insurance. Through private online consultations, patients can receive both over-the-counter and prescription treatments via same-day pharmacy pickup or free discreet delivery, making equitable healthcare accessible to women across all 50 states. To learn more about Wisp, please visit www.hellowisp.com.

Footnotes:

1. CAGR calculated using the periods from January through July 2020 to January through July 2024.

ABOUT WISP:

Wisp is a women’s health company on a mission to make sexual and reproductive healthcare more inclusive, cost-effective, and accessible. Available in all 50 states, Wisp provides discreet treatments online with a comprehensive selection of products and telehealth services, including prescription medication, OTC prevention, at-home testing and more. Wisp is a growing and profitable company and is majority-owned by WELL Health Technologies Corp. To learn more, please visit hellowisp.com or follow @hellowisp on Facebook, Instagram, TikTok and YouTube.